NKMax America To Present Data from its Natural Killer Cell Immunotherapy Clinical Program at the ASCO20 Virtual Scientific Program

SANTA ANA, Calif., April 30, 2020 (GLOBE NEWSWIRE) — NKMax America, a biotechnology company harnessing the power of the body’s immune system through the development of Natural Killer (NK) cell therapies, today disclosed its three abstract titles related to SNK-01, an autologous NK cell adoptive immunotherapy for the upcoming 2020 American Society of Clinical Oncology (ASCO) annual meeting, being held virtually.